C. Q. Lai, D. K. Arnett, D. Corella, R. J. Straka, M. Y. Tsai, J. M. Peacock, X. Adiconis, L. D. Parnell, J. E. Hixson, et al., “Fenofibrate Effect on Triglyceride and Postprandial Response of Apolipoprotein A5 Variants, The GOLDN Study,” Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 27, No. 6, 2007, pp. 1417-1425.

has been cited by the following article:

• TITLE: The Pharmacogenomic Consideration of Lipid Homeostasis: Role of Pharmacist in Ethical and Economic Consideration

  AUTHORS: Paul Serafin, Mohammad Newaz

  KEYWORDS: Pharmacogenomics; Lipid; Atherosclerosis; CVD; Pharmacogenetic Testing

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.4 No.1, January 30, 2013

  ABSTRACT: Usage of lipid lowering drugs is a common therapeutic steps in preventing or treating diseases. With the advent of Pharmacogenetics and Pharmacogenomics, it is now important to understand the implication of pharmacogenetic testing in patient care. Ethical and economic concerns are wide considered to be an issue in a pharmacy setting and it is important that the health care professionals in the pharmacy setting need to be aware. This article encompasses current pharmacogenomic information that is relevant to lipid homeostasis and addressed the concerns of patient that may be a factor in ultimate decision making process.